What is a PDA?
In the womb, there is a vessel that connects the two major arteries emerging from the baby’s (fetus) heart. This is a normal part of the fetal circulatory system. Once the baby begins to receive oxygen through its own lungs at birth, this connecting vessel is no longer needed and spontaneously closes in most people. However, for various reasons, it can rarely remain open. This persistent connection is medically termed patent ductus arteriosus (PDA) (Patent: Open, Ductus: Connection, Arteriosus: Artery).
Damar bağlantısının kapanarak bir bant haline gelmesi (Nationwide Children’s Hospital web sitesinden alıntılanarak yeniden düzenlenmiştir.)

Damar bağlantısının açık kalması (Nationwide Children’s Hospital web sitesinden alıntılanarak yeniden düzenlenmiştir.)

PDA’nın tıpayla ameliyatsız kapatılması (Nationwide Children’s Hospital web sitesinden alıntılanarak yeniden düzenlenmiştir.)
What is PDA shutdown?
Because of the blood leaking through the PDA, the left side of the heart fills with more blood than it should, and as a result, the left side of the heart may enlarge over time. If the heart has enlarged, the PDA must be closed. However, in very advanced cases, closing the PDA unfortunately does not provide any benefit; it may even cause harm. If the PDA is very small—meaning the amount of blood leaking is minimal, causing no symptoms in the patient, and the heart is of normal size—there is no need to close the PDA.
What is the success rate of closing a PDA using a non-surgical method?
In general, the technical success rate is over 95%.What are the risks of turning off a PDA?
As with any invasive procedure, this procedure also carries certain risks. Serious complications, such as the device dislodging or a blood clot forming on the device, occur in 3 out of every 100 people; death occurs in 1 out of every 1,000 people. You may be justified in feeling concerned about these risks; but remember: these complications are rare. What matters is whether the procedure is truly necessary. If the decision has been made in accordance with current scientific data and guidelines, avoiding this procedure actually means exposing yourself to a much higher risk of heart failure.

What tests are performed before the PDA closure procedure, and for what purpose?
- Blood test: For checking other conditions such as anemia, kidney failure, and infection.
- ECHO (Heart ultrasound): To confirm the presence of PDA and to determine whether there is any additional heart disease.
- CT (Computed tomography): To plan the technique to be applied during the procedure and to determine the type of device to be used.
How long does the process take?
Usually 1 hour. However, depending on the anatomical characteristics of the PDA, this duration may be shorter or longer.Is the procedure performed by stopping the heart, as is done in heart surgery?
No. It is done while the heart is beating.Is there any pain during the PDA closure procedure?
No. The site of the vascular access is numbed, and the patient remains awake throughout the procedure. Sedatives may be administered to help alleviate stress.When will I be discharged after the procedure?
Most patients are discharged the next day.Will the PDA shutdown device come loose over time?
Although cases in which the implant has shifted from its original position have been reported in the literature, this is a very rare occurrence. Once the implant has been covered by tissue within a few months, it is no longer possible for it to move.Can the device be felt in the body after the procedure?
No.Will the device remain in the body for life?
Yes. There is no question of removing the device.Will I need to take blood-thinning medication after the PDA closure procedure?
Yes. Generally, low-dose aspirin is taken for 6 months. After the 6th month, there is no need to continue taking blood-thinning medication.References
- Stout KK, Daniels CJ, Aboulhosn JA, et al. AHA/ACC Guideline for the management of adults with congenital heart disease. Circulation. 2019 Apr 2;139(14):e698-e800.
- Baumgartner H, De Backer J, Babu-Narayan SV, et al. ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021 Feb 11;42(6):563-645.